This study is currently not recruiting participants.

Inhaled Nitric Oxide for the Treatment of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth

Investigating the Impact of an Investigational Medication in Preventing Bronchopulmonary Dysplasia in Premature Infants

Not Recruiting
1 years - 1 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to study how well a drug called nitric oxide (NO) works in preventing Bronchopulmonary Dysplasia in premature infants.

Detailed description of study

The purpose of this study is to study how well a drug called nitric oxide (NO) works in preventing Bronchopulmonary Dysplasia in premature infants.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchopulmonary Dysplasia (BPD)
  • Age: 1 years - 1 years
  • Gender: All

This study investigates how well an investigational medication works in preventing Bronchopulmonary Dysplasia in premature infants. Bronchopulmonary Dysplasia is a chronic lung condition that affects newborns, especially those who are born prematurely.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.

  • Who can participate: Participants must be premature infants meeting specific age criteria and other key eligibility factors.
  • Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1011003807 (0912-15)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team